IOVA – iovance biotherapeutics, inc. (US:NASDAQ)

News

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer [Yahoo! Finance]
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target lowered by analysts at Piper Sandler from $10.00 to $7.50. They now have a "neutral" rating on the stock.
What's Wrong With Iovance Biotherapeutics Stock? [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com